The summarized evidence suggests that metformin can reduce body weight, enhance insulin sensitivity, and improve glucose metabolism by promoting BAT thermogenic activity in preclinical models of obesity. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.